{
    "clinical_study": {
        "@rank": "67001", 
        "arm_group": {
            "arm_group_label": "V110 Vaccination", 
            "arm_group_type": "Experimental", 
            "description": "Single, 0.5-mL intramuscular injection of V110 on Day 1"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if Pneumococcal Vaccine (V110) is safe and\n      immunogenic in participants from the Russian population who are 50 years of age and older or\n      2 to 49 years of age and at increased risk for pneumococcal disease"
        }, 
        "brief_title": "A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumococcal Vaccine (V110) in Participants From the Russian Population (V110-018 AM1)", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Pneumococcal Disease", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  For participants 50 years of age or older: any underlying chronic illness must be in\n             stable condition\n\n          -  For participants 2 to 49 years of age: participant has an increased risk for\n             pneumococcal disease as a result of one of the following: chronic cardiovascular\n             disease, chronic pulmonary disease, diabetes mellitus, alcoholism, chronic liver\n             disease, cerebrospinal fluid leaks, functional or anatomic asplenia, sickle cell\n             anemia, living in a special environment or social setting such as crowded, closed\n             communities\n\n          -  Male, or female not of reproductive potential, or female of reproductive potential\n             who agrees to remain abstinent or to use 2 acceptable methods of contraception\n             through 6 weeks after study vaccination\n\n        Exclusion Criteria:\n\n          -  Received prior vaccination with pneumococcal vaccine\n\n          -  Has known or suspected immune dysfunction or conditions associated with\n             immunosuppression, or is receiving immunosuppressive chemotherapy, including\n             long-term systemic corticosteroids\n\n          -  Has history of autoimmune disease\n\n          -  Received a licensed live virus vaccine within 3 months before or is scheduled within\n             3 months after study vaccination\n\n          -  Received a licensed inactivated vaccine within 28 days before or is scheduled within\n             28 days after study vaccination\n\n          -  Received an investigational drug or other investigational vaccine within 2 months\n             before or is scheduled within 28 days after study vaccination (3 months if a live\n             virus vaccine)\n\n          -  Received any blood product or immunoglobulin preparation within 6 months before or 28\n             days after study vaccination\n\n          -  Hospitalized for acute illness within 3 months before study vaccination\n\n          -  Is a pregnant woman or nursing mother\n\n          -  History of invasive pneumococcal disease or of other culture-positive pneumococcal\n             disease\n\n          -  History of fever illness within 3 days before study vaccination\n\n          -  Received antibiotic therapy for any acute illness within 7 days before study\n             vaccination\n\n          -  Hypersensitivity to any components of the vaccine, including phenol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "102", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01734239", 
            "org_study_id": "V110-018"
        }, 
        "intervention": {
            "arm_group_label": "V110 Vaccination", 
            "description": "Vaccine contains 25 \u00b5g of each of the 23 pneumococcal polysaccharides serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F", 
            "intervention_name": "V110", 
            "intervention_type": "Biological", 
            "other_name": "PNEUMOVAX\u2122 23"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 13, 2013", 
        "number_of_arms": "1", 
        "official_title": "A Phase III, Open-Label Clinical Trial to Study the Safety and Immunogenicity of V110 in Subjects 50 Years of Age and Older and in Subjects 2 to 49 Years of Age at Increased Risk for Pneumococcal Disease, From the Russian Population", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Russia: Pharmacological Committee, Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Geometric Mean Concentration of Antibodies to Pneumococcal Serotypes Contained in the Vaccine", 
                "safety_issue": "No", 
                "time_frame": "Day 28 after vaccination"
            }, 
            {
                "measure": "Percentage of Participants with \u22652-fold Change from Baseline in Antibodies to Pneumococcal Serotypes Contained in the Vaccine", 
                "safety_issue": "No", 
                "time_frame": "Day 28 after vaccination"
            }, 
            {
                "measure": "Number of Participants with Elevated Body Temperature (\u226537.6\u00b0C axillary, \u226538.0\u00b0C oral or equivalent)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 5 days after vaccination"
            }, 
            {
                "measure": "Number of Participants Reporting Solicited Injection-Site Reactions (Redness, Swelling, Pain/Tenderness)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 14 days after vaccination"
            }, 
            {
                "measure": "Number of Participants Reporting Serious Adverse Experiences", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 days after vaccination"
            }
        ], 
        "removed_countries": {
            "country": "Russian Federation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01734239"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}